849-001 (RM 615) KRYSTAL-1
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
Cancer Types: Lung Cancer, Colon and Rectal Cancer, Pancreatic CancerLines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT03785249?term=849-001&draw=2&rank=1
Practices offering this clinical trial:
AK112-301 (LUN 515)
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05184712?term=AK112-301&rank=1
Practices offering this clinical trial:
ALKS 4230-007 (GYN 112) ARTISTRY-7
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Types: Ovarian and Endometrial CancerLines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05092360?term=ALKS+4230-007&draw=2&rank=1
Practices offering this clinical trial:
Bo44157 (GU 220)
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
Cancer Types: Bladder CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT05645692
Practices offering this clinical trial:
D926NC00001 (LUN 512) AVANZAR
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/study/NCT05687266?term=D926NC00001&rank=1
Practices offering this clinical trial:
D926XC00001 (BRE 409) TROPION-Breast03
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Cancer Types: Breast CancerLines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/study/NCT05629585?term=D926XC00001&rank=1
Practices offering this clinical trial:
J2J-MC-JZLH (BRE 402) EMBER-4
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Cancer Types: Breast CancerLines of Therapy: Adjuvant
More details: https://clinicaltrials.gov/ct2/show/NCT05514054?term=j2j-mc-jzlh&draw=2&rank=1
Practices offering this clinical trial:
KRT-232-112 (LUN 469)
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Cancer Types: Lung CancerLines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05027867
Practices offering this clinical trial:
NIT-119 (LUN 463)
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://clinicaltrials.gov/ct2/show/NCT04984811?term=NIT-119&draw=2&rank=1
Practices offering this clinical trial:
ONC-392-001 (MULTI 67) PRESERVE-001
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Cancer Types: Lung Cancer, Solid TumorsLines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT04140526?term=ONC-392-001&draw=2&rank=1
Practices offering this clinical trial:
RMC-4630-03 (LUN 468)
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Cancer Types: Lung CancerLines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/ct2/show/NCT05054725
Practices offering this clinical trial:
TTX-030-003 (GI 361)
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma
Cancer Types: Pancreatic CancerLines of Therapy: 1st Line Metastatic and Locally Advanced
More details: https://classic.clinicaltrials.gov/ct2/show/NCT06119217
Practices offering this clinical trial:
XPORT-EC-042 (GYN 117)
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Cancer Types: Ovarian and Endometrial CancerLines of Therapy: 2nd Line Metastatic
More details: https://clinicaltrials.gov/study/NCT05611931?term=XPORT-EC-042&rank=1
Practices offering this clinical trial:
Zn-c3-005 (GYN 45) DENALI
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Cancer Types: Ovarian and Endometrial CancerLines of Therapy: 2nd Line Metastatic, 3rd Line + Metastatic
More details: https://clinicaltrials.gov/study/NCT05128825?term=Zn-c3-005&rank=1
Practices offering this clinical trial: